Skip to main content
Erschienen in: Monatsschrift Kinderheilkunde 4/2019

12.03.2019 | Epilepsie | Leitthema

Neue Systematik der Epilepsien und aktuelle Therapieempfehlungen

verfasst von: Prof. Dr. B. A. Neubauer, Prof. Dr. A. Hahn

Erschienen in: Monatsschrift Kinderheilkunde | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die aktuelle Klassifikation der Epilepsien aus dem Jahr 2017 gleicht stark der Version des Jahres 1989. Die Versuche einer Reklassifikation in den Jahren 2001, 2006 und 2010 brachten aus heutiger Sicht keine wesentlichen Verbesserungen und wurden von der internationalen Gemeinschaft der Epileptologen nicht gut angenommen. Der jetzige Vorschlag überzeugt durch einen pragmatischen Ansatz und führt neue Konzepte nur dort ein, wo neue wissenschaftlich belegbare Befunde vorliegen. Anfallsform, Art der Epilepsie, Einteilung des Epilepsiesyndroms, Ätiologie und Komorbidität sind die wichtigsten Bestandteile.
Die Zahl der verfügbaren Antiepileptika nimmt fast von Jahr zu Jahr weiter zu. Dies eröffnet für den einzelnen Patienten neue therapeutische Alternativen bei Unverträglichkeit oder Versagen der Standardtherapie. Betrachtet man aber die gesamte Gruppe der Betroffenen, bleibt der Anteil der anfallsfrei werdenden Patienten fast gleich. Der entscheidende Vorteil einer Vielzahl neuer Antiepileptika liegt in ihrer guten kognitiven Verträglichkeit. Die Neuerungen der Behandlungskonzepte bei West-Syndrom, Absence-Epilepsien, strukturell/metabolischen, genetisch generalisierten, genetisch fokalen Epilepsien und dem Dravet-Syndrom werden berichtet.
Literatur
1.
Zurück zum Zitat Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S, Mathern GW, Moshé SL, Nordli DR, Perucca E, Tomson T, Wiebe S, Zhang YH, Zuberi SM (2017) ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 58(4):512–521. https://doi.org/10.1111/epi.13709 CrossRefPubMedPubMedCentral Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S, Mathern GW, Moshé SL, Nordli DR, Perucca E, Tomson T, Wiebe S, Zhang YH, Zuberi SM (2017) ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 58(4):512–521. https://​doi.​org/​10.​1111/​epi.​13709 CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, Lagae L, Moshé SL, Peltola J, Roulet PE, Scheffer IE, Zuberi SM (2017a) Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia 58(4):522–530CrossRef Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, Lagae L, Moshé SL, Peltola J, Roulet PE, Scheffer IE, Zuberi SM (2017a) Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia 58(4):522–530CrossRef
3.
Zurück zum Zitat Fisher RS, Cross JH, D’Souza C, French JA, Haut SR, Higurashi N, Hirsch E, Jansen FE, Lagae L, Moshé SL, Peltola J, Roulet Perez E, Scheffer IE, Schulze-Bonhage A, Somerville E, Sperling M, Yacubian EM, Zuberi SM (2017b) Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia 58(4):531–542CrossRef Fisher RS, Cross JH, D’Souza C, French JA, Haut SR, Higurashi N, Hirsch E, Jansen FE, Lagae L, Moshé SL, Peltola J, Roulet Perez E, Scheffer IE, Schulze-Bonhage A, Somerville E, Sperling M, Yacubian EM, Zuberi SM (2017b) Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia 58(4):531–542CrossRef
5.
Zurück zum Zitat Heyne HO, Singh T, Stamberger H et al (2018) De novo variants in neurodevelopmental disorders with epilepsy. Nat Genet 50(7):1048–1053CrossRef Heyne HO, Singh T, Stamberger H et al (2018) De novo variants in neurodevelopmental disorders with epilepsy. Nat Genet 50(7):1048–1053CrossRef
6.
Zurück zum Zitat Chiang SS, Khan FA, Milstein MB, Tolman AW, Benedetti A, Starke JR, Becerra MC (2014) Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis 14(10):947–957CrossRef Chiang SS, Khan FA, Milstein MB, Tolman AW, Benedetti A, Starke JR, Becerra MC (2014) Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis 14(10):947–957CrossRef
7.
Zurück zum Zitat Armangue T, Spatola M, Vlagea A et al (2018) Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol 17(9):760–772CrossRef Armangue T, Spatola M, Vlagea A et al (2018) Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol 17(9):760–772CrossRef
8.
Zurück zum Zitat Dalmau J, Graus F (2018) Antibody-Mediated Encephalitis. N Engl J Med 378(9):840–851CrossRef Dalmau J, Graus F (2018) Antibody-Mediated Encephalitis. N Engl J Med 378(9):840–851CrossRef
9.
Zurück zum Zitat Wells E, Hacohen Y, Waldman A et al (2018) Neuroimmune disorders of the central nervous system in children in the molecular era. Nat Rev Neurol 14(7):433–445CrossRef Wells E, Hacohen Y, Waldman A et al (2018) Neuroimmune disorders of the central nervous system in children in the molecular era. Nat Rev Neurol 14(7):433–445CrossRef
10.
Zurück zum Zitat Nosadini M, Mohammad SS, Corazza F, Ruga EM, Kothur K, Perilongo G, Frigo AC, Toldo I, Dale RC, Sartori S (2017) Herpes simplex virus-induced anti-N-methyl-d-aspartate receptor encephalitis: a systematic literature review with analysis of 43 cases. Dev Med Child Neurol 59(8):796–805CrossRef Nosadini M, Mohammad SS, Corazza F, Ruga EM, Kothur K, Perilongo G, Frigo AC, Toldo I, Dale RC, Sartori S (2017) Herpes simplex virus-induced anti-N-methyl-d-aspartate receptor encephalitis: a systematic literature review with analysis of 43 cases. Dev Med Child Neurol 59(8):796–805CrossRef
11.
Zurück zum Zitat Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, Engel J, French J, Glauser TA, Mathern GW, Moshé SL, Nordli D, Plouin P, Scheffer IE (2010) Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 51(4):676–685CrossRef Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, Engel J, French J, Glauser TA, Mathern GW, Moshé SL, Nordli D, Plouin P, Scheffer IE (2010) Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 51(4):676–685CrossRef
12.
Zurück zum Zitat Moavero R, Pisani LR, Pisani F, Curatolo P (2018) Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy. Expert Opin Drug Saf 17(10):1015–1028CrossRef Moavero R, Pisani LR, Pisani F, Curatolo P (2018) Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy. Expert Opin Drug Saf 17(10):1015–1028CrossRef
13.
Zurück zum Zitat Meschede C, Witt JA, Rademacher M, von Wrede RD, Elger CE, Helmstaedter C (2018) Evaluating the longer-term cognitive effects of adjunctive perampanel compared to lacosamide in a naturalistic outpatient setting. Seizure 58:141–146CrossRef Meschede C, Witt JA, Rademacher M, von Wrede RD, Elger CE, Helmstaedter C (2018) Evaluating the longer-term cognitive effects of adjunctive perampanel compared to lacosamide in a naturalistic outpatient setting. Seizure 58:141–146CrossRef
14.
Zurück zum Zitat Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, O’Callaghan FJ, Verity CM, Osborne JP (2004) The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet 364(9447):1773–1778CrossRef Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, O’Callaghan FJ, Verity CM, Osborne JP (2004) The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet 364(9447):1773–1778CrossRef
15.
Zurück zum Zitat O’Callaghan FJ, Edwards SW, Alber FD, Hancock E, Johnson AL, Kennedy CR, Likeman M, Lux AL, Mackay M, Mallick AA, Newton RW, Nolan M, Pressler R, Rating D, Schmitt B, Verity CM, Osborne JP, Participating investigators (2017) Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol 16(1):33–42CrossRef O’Callaghan FJ, Edwards SW, Alber FD, Hancock E, Johnson AL, Kennedy CR, Likeman M, Lux AL, Mackay M, Mallick AA, Newton RW, Nolan M, Pressler R, Rating D, Schmitt B, Verity CM, Osborne JP, Participating investigators (2017) Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol 16(1):33–42CrossRef
16.
Zurück zum Zitat O’Callaghan FJ, Edwards SW, (ICISS) investigators (2018) Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. Lancet Child Adolesc Health 2(10):715–725CrossRef O’Callaghan FJ, Edwards SW, (ICISS) investigators (2018) Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. Lancet Child Adolesc Health 2(10):715–725CrossRef
18.
Zurück zum Zitat Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC, Childhood Absence Epilepsy Study Group (2010) Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 362(9):790–799CrossRef Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC, Childhood Absence Epilepsy Study Group (2010) Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 362(9):790–799CrossRef
19.
Zurück zum Zitat Schmitt B, Kovacevic-Preradovic T, Critelli H, Molinari L (2007) Is ethosuximide a risk factor for generalised tonic-clonic seizures in absence epilepsy? Neuropediatrics 38(2):83–87CrossRef Schmitt B, Kovacevic-Preradovic T, Critelli H, Molinari L (2007) Is ethosuximide a risk factor for generalised tonic-clonic seizures in absence epilepsy? Neuropediatrics 38(2):83–87CrossRef
20.
Zurück zum Zitat Shinnar S, Cnaan A, Hu F, Clark P, Dlugos D, Hirtz DG, Masur D, Mizrahi EM, Moshé SL, Glauser TA, Childhood Absence Epilepsy Study Group (2015) Long-term outcomes of generalized tonic-clonic seizures in a childhood absence epilepsy trial. Neurology 85(13):1108–1114CrossRef Shinnar S, Cnaan A, Hu F, Clark P, Dlugos D, Hirtz DG, Masur D, Mizrahi EM, Moshé SL, Glauser TA, Childhood Absence Epilepsy Study Group (2015) Long-term outcomes of generalized tonic-clonic seizures in a childhood absence epilepsy trial. Neurology 85(13):1108–1114CrossRef
21.
Zurück zum Zitat Ragona F, Matricardi S, Castellotti B, Patrini M, Freri E, Binelli S, Granata T (2014) Refractory absence epilepsy and glut1 deficiency syndrome: a new case report and literature review. Neuropediatrics 45(5):328–332CrossRef Ragona F, Matricardi S, Castellotti B, Patrini M, Freri E, Binelli S, Granata T (2014) Refractory absence epilepsy and glut1 deficiency syndrome: a new case report and literature review. Neuropediatrics 45(5):328–332CrossRef
22.
Zurück zum Zitat Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF, Abou-Khalil B, Burakgazi-Dalkilic E, Park EL, Stern J, Hirtz D, Nespeca M, Gidal B, Faught E, French J (2018) Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy: report of the American epilepsy society and the guideline development, dissemination, and implementation subcommittee of the American academy of neurology. Epilepsy Curr 18(4):260–268CrossRef Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF, Abou-Khalil B, Burakgazi-Dalkilic E, Park EL, Stern J, Hirtz D, Nespeca M, Gidal B, Faught E, French J (2018) Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy: report of the American epilepsy society and the guideline development, dissemination, and implementation subcommittee of the American academy of neurology. Epilepsy Curr 18(4):260–268CrossRef
23.
Zurück zum Zitat Arzimanoglou A, D’Cruz O, Nordli D, Shinnar S, Holmes GL, Pediatric Epilepsy Academic Consortium for Extrapolation (PEACE). (2018) A review of the new antiepileptic drugs for focal-onset seizures in pediatrics: role of extrapolation. Paediatr Drugs 20(3):249–264CrossRef Arzimanoglou A, D’Cruz O, Nordli D, Shinnar S, Holmes GL, Pediatric Epilepsy Academic Consortium for Extrapolation (PEACE). (2018) A review of the new antiepileptic drugs for focal-onset seizures in pediatrics: role of extrapolation. Paediatr Drugs 20(3):249–264CrossRef
24.
Zurück zum Zitat Lattanzi S, Zaccara G, Giovannelli F, Grillo E, Nardone R, Silvestrini M, Trinka E, Brigo F (2019) Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis. Acta Neurol Scand 139(1):33–41CrossRef Lattanzi S, Zaccara G, Giovannelli F, Grillo E, Nardone R, Silvestrini M, Trinka E, Brigo F (2019) Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis. Acta Neurol Scand 139(1):33–41CrossRef
25.
Zurück zum Zitat Rating D, Wolf C, Bast T (2000) Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Sulthiame Study Group. Epilepsia 41(10):1284–1288CrossRef Rating D, Wolf C, Bast T (2000) Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Sulthiame Study Group. Epilepsia 41(10):1284–1288CrossRef
26.
Zurück zum Zitat Fujii A, Oguni H, Hirano Y, Osawa M (2010) Atypical benign partial epilepsy: recognition can prevent pseudocatastrophe. Pediatr Neurol 43(6):411–419CrossRef Fujii A, Oguni H, Hirano Y, Osawa M (2010) Atypical benign partial epilepsy: recognition can prevent pseudocatastrophe. Pediatr Neurol 43(6):411–419CrossRef
27.
Zurück zum Zitat Bourgeois BF (2000) Drug treatment of benign focal epilepsies of childhood. Epilepsia 41(8):1057–1058CrossRef Bourgeois BF (2000) Drug treatment of benign focal epilepsies of childhood. Epilepsia 41(8):1057–1058CrossRef
29.
Zurück zum Zitat Knupp KG, Wirrell EC (2018) Treatment strategies for Dravet syndrome. Cns Drugs 32(4):335–350CrossRef Knupp KG, Wirrell EC (2018) Treatment strategies for Dravet syndrome. Cns Drugs 32(4):335–350CrossRef
30.
Zurück zum Zitat Devinsky O, Nabbout R, Miller I, Laux L, Zolnowska M, Wright S, Roberts C (2018a) Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial. Epilepsia 60(2):294–302CrossRef Devinsky O, Nabbout R, Miller I, Laux L, Zolnowska M, Wright S, Roberts C (2018a) Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial. Epilepsia 60(2):294–302CrossRef
31.
Zurück zum Zitat Schoonjans A, Paelinck BP, Marchau F, Gunning B, Gammaitoni A, Galer BS, Lagae L, Ceulemans B (2017) Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients. Eur J Neurol 24(2):309–314CrossRef Schoonjans A, Paelinck BP, Marchau F, Gunning B, Gammaitoni A, Galer BS, Lagae L, Ceulemans B (2017) Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients. Eur J Neurol 24(2):309–314CrossRef
32.
Zurück zum Zitat Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM, GWPCARE3 Study Group (2018b) Effect of Cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med 378(20):1888–1897CrossRef Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM, GWPCARE3 Study Group (2018b) Effect of Cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med 378(20):1888–1897CrossRef
33.
Zurück zum Zitat Lagae L, Schoonjans AS, Gammaitoni AR, Galer BS, Ceulemans B (2018) A pilot, open-label study of the effectiveness and tolerability of low-dose ZX008 (fenfluramine HCl) in Lennox-Gastaut syndrome. Epilepsia 59(10):1881–1888CrossRef Lagae L, Schoonjans AS, Gammaitoni AR, Galer BS, Ceulemans B (2018) A pilot, open-label study of the effectiveness and tolerability of low-dose ZX008 (fenfluramine HCl) in Lennox-Gastaut syndrome. Epilepsia 59(10):1881–1888CrossRef
34.
Zurück zum Zitat Coppola G, Piccorossi A, Operto FF, Verrotti A (2017) Anticonvulsant drugs for generalized tonic-clonic epilepsy. Expert Opin Pharmacother 18(9):925–936CrossRef Coppola G, Piccorossi A, Operto FF, Verrotti A (2017) Anticonvulsant drugs for generalized tonic-clonic epilepsy. Expert Opin Pharmacother 18(9):925–936CrossRef
35.
Zurück zum Zitat Stewart JD, Horvath R, Baruffini E, Ferrero I, Bulst S, Watkins PB, Fontana RJ, Day CP, Chinnery PF (2010) Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 52(5):1791–1796CrossRef Stewart JD, Horvath R, Baruffini E, Ferrero I, Bulst S, Watkins PB, Fontana RJ, Day CP, Chinnery PF (2010) Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 52(5):1791–1796CrossRef
36.
Zurück zum Zitat Yang YC, Jou ST, Chang YH, Liang JS, Lee WT (2004) Hemophagocytic syndrome associated with antiepileptic drug. Pediatr Neurol 30(5):358–360CrossRef Yang YC, Jou ST, Chang YH, Liang JS, Lee WT (2004) Hemophagocytic syndrome associated with antiepileptic drug. Pediatr Neurol 30(5):358–360CrossRef
Metadaten
Titel
Neue Systematik der Epilepsien und aktuelle Therapieempfehlungen
verfasst von
Prof. Dr. B. A. Neubauer
Prof. Dr. A. Hahn
Publikationsdatum
12.03.2019
Verlag
Springer Medizin
Erschienen in
Monatsschrift Kinderheilkunde / Ausgabe 4/2019
Print ISSN: 0026-9298
Elektronische ISSN: 1433-0474
DOI
https://doi.org/10.1007/s00112-019-0676-6

Weitere Artikel der Ausgabe 4/2019

Monatsschrift Kinderheilkunde 4/2019 Zur Ausgabe

Einführung zum Thema

Neuropädiatrie

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.